BACKGROUND: l-Carnitine, an abundant nutrient in red meat, accelerates atherosclerosis in mice via gut microbiota-dependent formation of trimethylamine (TMA) and trimethylamine N-oxide (TMAO) via a multistep pathway involving an atherogenic intermediate, γ-butyrobetaine (γBB). The contribution of γBB in gut microbiota-dependent l-carnitine metabolism in humans is unknown. METHODS: Omnivores and vegans/vegetarians ingested deuterium-labeled l-carnitine (d3-l-carnitine) or γBB (d9-γBB), and both plasma metabolites and fecal polymicrobial transformations were examined at baseline, following oral antibiotics, or following chronic (≥2 months) l-carnitine supplementation. Human fecal commensals capable of performing each step of the l-carnitine→γBB→TMA transformation were identified. RESULTS: Studies with oral d3-l-carnitine or d9-γBB before versus after antibiotic exposure revealed gut microbiota contribution to the initial 2 steps in a metaorganismal l-carnitine→γBB→TMA→TMAO pathway in subjects. Moreover, a striking increase in d3-TMAO generation was observed in omnivores over vegans/vegetarians (>20-fold; P = 0.001) following oral d3-l-carnitine ingestion, whereas fasting endogenous plasma l-carnitine and γBB levels were similar in vegans/vegetarians (n = 32) versus omnivores (n = 40). Fecal metabolic transformation studies, and oral isotope tracer studies before versus after chronic l-carnitine supplementation, revealed that omnivores and vegans/vegetarians alike rapidly converted carnitine to γBB, whereas the second gut microbial transformation, γBB→TMA, was diet inducible (l-carnitine, omnivorous). Extensive anaerobic subculturing of human feces identified no single commensal capable of l-carnitine→TMA transformation, multiple community members that converted l-carnitine to γBB, and only 1 Clostridiales bacterium, Emergencia timonensis, that converted γBB to TMA. In coculture, E. timonensis promoted the complete l-carnitine→TMA transformation. CONCLUSION: In humans, dietary l-carnitine is converted into the atherosclerosis- and thrombosis-promoting metabolite TMAO via 2 sequential gut microbiota-dependent transformations: (a) initial rapid generation of the atherogenic intermediate γBB, followed by (b) transformation into TMA via low-abundance microbiota in omnivores, and to a markedly lower extent, in vegans/vegetarians. Gut microbiota γBB→TMA/TMAO transformation is induced by omnivorous dietary patterns and chronic l-carnitine exposure. TRIAL REGISTRATION: ClinicalTrials.gov NCT01731236. FUNDING: NIH and Office of Dietary Supplements grants HL103866, HL126827, and DK106000, and the Leducq Foundation.
BACKGROUND:l-Carnitine, an abundant nutrient in red meat, accelerates atherosclerosis in mice via gut microbiota-dependent formation of trimethylamine (TMA) and trimethylamine N-oxide (TMAO) via a multistep pathway involving an atherogenic intermediate, γ-butyrobetaine (γBB). The contribution of γBB in gut microbiota-dependent l-carnitine metabolism in humans is unknown. METHODS: Omnivores and vegans/vegetarians ingested deuterium-labeled l-carnitine (d3-l-carnitine) or γBB (d9-γBB), and both plasma metabolites and fecal polymicrobial transformations were examined at baseline, following oral antibiotics, or following chronic (≥2 months) l-carnitine supplementation. Human fecal commensals capable of performing each step of the l-carnitine→γBB→TMA transformation were identified. RESULTS: Studies with oral d3-l-carnitine or d9-γBB before versus after antibiotic exposure revealed gut microbiota contribution to the initial 2 steps in a metaorganismal l-carnitine→γBB→TMA→TMAO pathway in subjects. Moreover, a striking increase in d3-TMAO generation was observed in omnivores over vegans/vegetarians (>20-fold; P = 0.001) following oral d3-l-carnitine ingestion, whereas fasting endogenous plasma l-carnitine and γBB levels were similar in vegans/vegetarians (n = 32) versus omnivores (n = 40). Fecal metabolic transformation studies, and oral isotope tracer studies before versus after chronic l-carnitine supplementation, revealed that omnivores and vegans/vegetarians alike rapidly converted carnitine to γBB, whereas the second gut microbial transformation, γBB→TMA, was diet inducible (l-carnitine, omnivorous). Extensive anaerobic subculturing of human feces identified no single commensal capable of l-carnitine→TMA transformation, multiple community members that converted l-carnitine to γBB, and only 1 Clostridiales bacterium, Emergencia timonensis, that converted γBB to TMA. In coculture, E. timonensis promoted the complete l-carnitine→TMA transformation. CONCLUSION: In humans, dietary l-carnitine is converted into the atherosclerosis- and thrombosis-promoting metabolite TMAO via 2 sequential gut microbiota-dependent transformations: (a) initial rapid generation of the atherogenic intermediate γBB, followed by (b) transformation into TMA via low-abundance microbiota in omnivores, and to a markedly lower extent, in vegans/vegetarians. Gut microbiota γBB→TMA/TMAO transformation is induced by omnivorous dietary patterns and chronic l-carnitine exposure. TRIAL REGISTRATION: ClinicalTrials.gov NCT01731236. FUNDING: NIH and Office of Dietary Supplements grants HL103866, HL126827, and DK106000, and the Leducq Foundation.
Authors: Benjamin T Wall; Francis B Stephens; Dumitru Constantin-Teodosiu; Kanagaraj Marimuthu; Ian A Macdonald; Paul L Greenhaff Journal: J Physiol Date: 2011-01-04 Impact factor: 5.182
Authors: Robert A Koeth; Bruce S Levison; Miranda K Culley; Jennifer A Buffa; Zeneng Wang; Jill C Gregory; Elin Org; Yuping Wu; Lin Li; Jonathan D Smith; W H Wilson Tang; Joseph A DiDonato; Aldons J Lusis; Stanley L Hazen Journal: Cell Metab Date: 2014-11-04 Impact factor: 27.287
Authors: Jill C Gregory; Jennifer A Buffa; Elin Org; Zeneng Wang; Bruce S Levison; Weifei Zhu; Matthew A Wagner; Brian J Bennett; Lin Li; Joseph A DiDonato; Aldons J Lusis; Stanley L Hazen Journal: J Biol Chem Date: 2014-12-30 Impact factor: 5.157
Authors: Diana M Shih; Zeneng Wang; Richard Lee; Yonghong Meng; Nam Che; Sarada Charugundla; Hannah Qi; Judy Wu; Calvin Pan; J Mark Brown; Thomas Vallim; Brian J Bennett; Mark Graham; Stanley L Hazen; Aldons J Lusis Journal: J Lipid Res Date: 2014-11-06 Impact factor: 5.922
Authors: Zeneng Wang; Elizabeth Klipfell; Brian J Bennett; Robert Koeth; Bruce S Levison; Brandon Dugar; Ariel E Feldstein; Earl B Britt; Xiaoming Fu; Yoon-Mi Chung; Yuping Wu; Phil Schauer; Jonathan D Smith; Hooman Allayee; W H Wilson Tang; Joseph A DiDonato; Aldons J Lusis; Stanley L Hazen Journal: Nature Date: 2011-04-07 Impact factor: 49.962
Authors: Adam B Roberts; Xiaodong Gu; Jennifer A Buffa; Alex G Hurd; Zeneng Wang; Weifei Zhu; Nilaksh Gupta; Sarah M Skye; David B Cody; Bruce S Levison; William T Barrington; Matthew W Russell; Jodie M Reed; Ashraf Duzan; Jennifer M Lang; Xiaoming Fu; Lin Li; Alex J Myers; Suguna Rachakonda; Joseph A DiDonato; J Mark Brown; Valentin Gogonea; Aldons J Lusis; Jose Carlos Garcia-Garcia; Stanley L Hazen Journal: Nat Med Date: 2018-08-06 Impact factor: 53.440
Authors: Ina Nemet; Prasenjit Prasad Saha; Nilaksh Gupta; Weifei Zhu; Kymberleigh A Romano; Sarah M Skye; Tomas Cajka; Maradumane L Mohan; Lin Li; Yuping Wu; Masanori Funabashi; Amanda E Ramer-Tait; Sathyamangla Venkata Naga Prasad; Oliver Fiehn; Federico E Rey; W H Wilson Tang; Michael A Fischbach; Joseph A DiDonato; Stanley L Hazen Journal: Cell Date: 2020-03-05 Impact factor: 41.582
Authors: Yoriko Heianza; Wenjie Ma; Joseph A DiDonato; Qi Sun; Eric B Rimm; Frank B Hu; Kathryn M Rexrode; JoAnn E Manson; Lu Qi Journal: J Am Coll Cardiol Date: 2020-02-25 Impact factor: 24.094